A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil(R)) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149.

Trial Profile

A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil(R)) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 10 Aug 2016

At a glance

  • Drugs Nintedanib (Primary) ; Doxorubicin liposomal
  • Indications Ovarian cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Aug 2014 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 14 Mar 2014 Trial status changed from recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top